Fluicell publishes 2023 Half-year report
Today, August 2023, Fluicell publishes the financial report for the period January 1 to June 30, 2023. The full report can be accessed through Fluicell’s investor relations page or using the link provided below.
CEO Victoire Viannay comments:
“Despite the uncertain situation in the life science sector overall, Fluicell continues to make progress towards our goal of transforming the way we treat diseases through innovative research technologies and tissue-based advanced therapies. For the second quarter of 2023, we report total revenues of 1,389 KSEK (818 KSEK), which corresponds to an increase of 70 percent compared to 2022. Net sales for the period amounted to 1,066 KSEK (487 KSEK), an increase of 119 percent. Total revenue for the first half of 2023 amounted to 3,507 KSEK (1,983 KSEK), which is an increase of 77 percent from the corresponding period last year.
We actively adapt to the current market conditions, diversify our customer base and explore new opportunities. Our focus on innovation and customer centricity remains unwavering.
The current state of the research technology market is contrasted by a very positive development in our ongoing regenerative medicine program in the area tissue-based therapies for type 1 diabetes treatment. Fluicell’s R&D team has made significant progress in the first half of 2023, and we can confidently say that we are currently further ahead than expected in our development. This progress means that we good hope to reach some of the milestones originally planned for 2024 as early as 2023.”
April – June 2023 in summary
- Operating income amounted to KSEK 1,389 (818)
- Net sales of KSEK 1,066 (487)
- Operating profit before depreciation, EBITDA, amounted to KSEK −7,159 (−6,991)
January – June 2023 in summary
- Operating income amounted to KSEK 3,507 (1,983)
- Net sales of KSEK 2,861 (1,330)
- Operating profit before depreciation, EBITDA, amounted to KSEK −12,373 (−11,745)